Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
10-year open follow-up of Cervarix immunogenicity and safety after study HPV-013
2008-000369-44Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2008
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection, cervical intraepithelial neoplasia (CIN) and Cervical Cancer (CC), sponsored by GSK. Primary endpoints: Anti-HPV-16 antibody titres, Anti-HPV-18 antibody titres and 2 more. Started Dec 2008; status: completed.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)Cervical Cancer (CC)
Beyond the preview
Go deeper on 2008-000369-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000369-44.